These benefits are reflected in the clinical guidelines published by the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE), which recommend use of a GLP-1RA or a sodium-glucose co-transporter-2 inhibitor (SGLT2i) with demonstrated CV risk reduction in patients with established/high risk of atherosclerotic CVD (ASCVD), while considering patient-specific factors [15, 17]
Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion
Immunization with a heat-killed preparation of the environmental bacterium Mycobacterium vaccae promotes stress resilience in mice (in Eng)
Our analysis is consistent with studies demonstrating that obesity, and particularly a high BMI, among patients with diabetes is a common characteristic of patients with rapid GET [28, 29]
What Paxlovids role is in this, and what the mechanism is for this rebound, is what I think is really important to understand. Adalja said that while rebound patients may still be contagious, anecdotally they seem to do OK in warding off the virus despite a rebound